Thermo Fisher Scientific Inc. $TMO Shares Sold by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% during the 4th quarter, HoldingsChannel reports. The fund owned 54,533 shares of the medical research company’s stock after selling 1,130 shares during the period. Thermo Fisher Scientific comprises 0.7% of Whittier Trust Co. of Nevada Inc.’s portfolio, making the stock its 29th largest position. Whittier Trust Co. of Nevada Inc.’s holdings in Thermo Fisher Scientific were worth $33,850,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. JPL Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the third quarter valued at $28,000. Highline Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 126.9% in the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 33 shares in the last quarter. Beacon Financial Strategies CORP acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at $29,000. Olistico Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $29,000. Finally, Cloud Capital Management LLC bought a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth about $31,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. This trade represents a 1.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 3.0%

TMO stock opened at $515.88 on Friday. The company has a quick ratio of 1.53, a current ratio of 1.89 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The firm’s 50-day simple moving average is $501.94 and its 200 day simple moving average is $549.89. The stock has a market cap of $191.71 billion, a PE ratio of 29.08, a price-to-earnings-growth ratio of 2.85 and a beta of 0.97.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, topping analysts’ consensus estimates of $6.45 by $0.12. The business had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter last year, the company earned $6.10 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were given a $0.47 dividend. The ex-dividend date was Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s payout ratio is currently 10.60%.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Citigroup lifted their target price on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Stifel Nicolaus upped their target price on Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a “buy” rating in a report on Friday, January 9th. UBS Group reaffirmed a “neutral” rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $631.25.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.